IFN-γ-primed induced mesenchymal stem cell (iMSC)-derived extracellular

Class

IFN-γ-primed induced mesenchymal stem cell (iMSC)-derived extracellular vesicle (exosome) therapy

Pathway

cell-free exosome cargo (enriched HSP70/miR-22-3p) modulating Th2 skin inflammation

Notes

original target text: IFN-γ-primed induced mesenchymal stem cell (iMSC)-derived extracellular vesicle (exosome) therapy

This mechanism refers to a cell-free biologic derived from mesenchymal stem cells (MSCs) that have been engineered or treated ("induced") and then exposed to interferon-gamma (IFN-γ), a signaling protein that primes cells toward a more actively immunomodulatory state. Rather than administering the living stem cells themselves, this approach harvests the extracellular vesicles (exosomes) that these primed cells release. Exosomes are small membrane-bound packets that cells use to communicate, carrying proteins, lipids, and small RNAs to nearby or distant cells. In this case, the exosomes are enriched in specific cargo, including the stress-response protein HSP70 and a small regulatory RNA (microRNA) called miR-22-3p, which together are thought to dampen a type of immune response known as Th2 inflammation. Th2 responses, driven by helper T cells producing cytokines like interleukin-4 and interleukin-13, underlie many allergic and atopic skin conditions. By delivering exosome cargo rather than live cells, this strategy aims to achieve targeted immune modulation while avoiding some risks associated with cell transplantation, such as uncontrolled proliferation or long-term engraftment. This general approach sits within a broader movement in regenerative medicine to harness the secreted signaling components of stem cells therapeutically, particularly for chronic inflammatory and allergic skin diseases.